drugset / Trial / NCT00212719

Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

NCT00212719

Phase 3 Completed 250 enrolled Ono Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of ONO-5920 in patients with involutional osteoporosis.

Timeline

Start
2003-05
Primary completion
2006-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Minodronic acid Small molecule 1 mg

Indications